Latest filing published 29 Apr 2026 for Kalray, €68k. Read the official filing
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Guy RIGAUD across 2 companies, led by Kalray and Phaxiam Therapeutics. We count 3 filings; the first trade dates from 23 June 2023 and the latest from 27 April 2026.
On the open market, the record shows 1 purchase worth €10k and 1 sale worth €68k. Sales outweigh purchases by €57k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2026 to date brings no purchases and 1 sale.
The record was last updated on 29 April 2026 with an open-market sale (€68k) in Kalray. The latest purchase dates back some time: it was published 754 days ago, on 23 September 2024. Between a trade and the moment it shows up on AMF, the median delay is 3 days. For comparison, MAR article 19 gives managers three business days to notify a trade. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations